Aiming to uncover a clinical relevance of the two clusters of patients, we performed survival analysis showing that breast cancer patients characterized by high levels of ITGA11, THBS1, FN1, EMP1, ITGA2, FYN, SPP1, and EMP2 (cluster 1) display a worse overall survival compared to the patients showing low expression of the aforementioned genes (cluster 2) (Fig. 5E). This evidence concerns the gene EMP1 and breast carcinoma.